The immunotherapeutic role of indoleamine 2,3‐dioxygenase in head and neck squamous cell carcinoma: A systematic review
Clinical Otolaryngology2021Vol. 46(5), pp. 919–934
Citations Over TimeTop 11% of 2021 papers
Abstract
IDO expression is increased in the TME of HNSCC, which correlates with poor prognosis. However, the exact mechanism of IDO-driven immune modulation in the TME is an enigma. Future translational studies should map IDO activity during HNSCC treatment and elucidate its precise role in the TME, such research will underpin the development of clinical trials establishing the efficacy of IDO inhibitors in HNSCC.
Related Papers
- → Indoleamine 2,3-Dioxygenase Does It(2015)3 cited
- → Pharmacological Inhibition of the Immunomodulatory Enzyme Indoleamine 2,3-Dioxygenase (IDO) Cooperatively Leverages Cytotoxic Chemotherapy(2005)
- → ATP promotes immunosuppressive MSCs inhibiting lymphocyte proliferation and expressing indoleamine dioxygenase(2017)
- Screening of the inhibitory activity of Korea local plant extracts against indoleamine 2,3-dioxygenase (IDO) = 한국 자생식물 추출물의 Indoleamine 2,3-dioxygenase (IDO) 저해활성(2011)
- 教15-2 妊娠免疫とIDO (Indoleamine 2, 3-dioxygenase)(アレルギー疾患の発症における免疫・神経・内分泌系のクロストーク,ミニシンポジウム,教育コース15(基礎・その他),第22回日本アレルギー学会春季臨床大会)(2010)